Literature DB >> 1623904

Rebound of plasma vancomycin levels after haemodialysis with highly permeable membranes.

J Böhler1, P Reetze-Bonorden, E Keller, A Kramer, P J Schollmeyer.   

Abstract

Vancomycin is usually given only once a week to haemodialysis (HD) patients. If highly permeable dialysis membranes are used, however, high clearance values have been reported, so the aim of the study was to determine whether high clearance of vancomycin resulted in sufficient drug elimination to induce subtherapeutic plasma levels after one week. In 18 chronic HD patients, treated with polysulfone dialyzers (1.2 m2), the pharmacokinetics of vancomycin were studied after administration of 1 g. Concentrations were determined by fluorescence polarisation immunoassay. At a blood flow of 219 ml.min-1, HD clearance of vancomycin was 62.3 ml.min-1. Immediately after dialysis plasma concentrations were 38% lower than predialysis levels. However, marked rebound in the vancomycin level was observed 5 h later, resulting in plasma levels only 16% lower than prior to dialysis. 3 HD treatments in 1 week removed about one third of the initial dose. After one week 15 of 18 patients still had a therapeutic plasma level (greater than 4 micrograms.ml-1). In conclusion, polysulfone membranes show high clearance of vancomycin. However, transfer of drug from blood to dialysate appears to be faster than from tissues to blood. Because of a marked rebound in plasma level after treatment, therapeutic drug concentrations will still be present in most patients after one week.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1623904     DOI: 10.1007/bf00265928

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  22 in total

1.  Elimination of vancomycin in patients on continuous arteriovenous hemodialysis.

Authors:  P Reetze-Bonorden; J Böhler; C Kohler; P Schollmeyer; E Keller
Journal:  Contrib Nephrol       Date:  1991       Impact factor: 1.580

2.  Markedly increased clearance of vancomycin during hemodialysis using polysulfone dialyzers.

Authors:  D M Lanese; P S Alfrey; B A Molitoris
Journal:  Kidney Int       Date:  1989-06       Impact factor: 10.612

3.  Vancomycin administration to hemodialysis patients.

Authors:  F Keller
Journal:  Clin Nephrol       Date:  1988-09       Impact factor: 0.975

4.  Percent reduction in blood urea concentration during hemodialysis (PRU). A simple and accurate method to estimate Kt/V urea.

Authors:  K K Jindal; A Manuel; M B Goldstein
Journal:  ASAIO Trans       Date:  1987 Jul-Sep

Review 5.  Vancomycin and the kidney.

Authors:  G B Appel; D B Given; L R Levine; G L Cooper
Journal:  Am J Kidney Dis       Date:  1986-08       Impact factor: 8.860

6.  Pharmacokinetics of vancomycin in patients undergoing haemodialysis and haemofiltration.

Authors:  V De Bock; D Verbeelen; V Maes; J Sennesael
Journal:  Nephrol Dial Transplant       Date:  1989       Impact factor: 5.992

7.  Pharmacokinetics of vancomycin in patients undergoing hemodialysis with polyacrylonitrile.

Authors:  J Torras; C Cao; M C Rivas; M Cano; E Fernandez; J Montoliu
Journal:  Clin Nephrol       Date:  1991-07       Impact factor: 0.975

Review 8.  Drug therapy in patients undergoing haemodialysis. Clinical pharmacokinetic considerations.

Authors:  C S Lee; T C Marbury
Journal:  Clin Pharmacokinet       Date:  1984 Jan-Feb       Impact factor: 6.447

Review 9.  Drug prescribing in renal failure: dosing guidelines for adults.

Authors:  W M Bennett; G R Aronoff; G Morrison; T A Golper; J Pulliam; M Wolfson; I Singer
Journal:  Am J Kidney Dis       Date:  1983-11       Impact factor: 8.860

10.  Vancomycin therapy for serious staphylococcal infections in chronic hemodialysis patients.

Authors:  M H Bierman; C A Needham-Walker; M Hammeke; J D Egan
Journal:  J Dial       Date:  1980
View more
  8 in total

1.  Dosage recommendation of vancomycin during haemodialysis with highly permeable membranes.

Authors:  J Zoer; A M Schrander-van der Meer; W T van Dorp
Journal:  Pharm World Sci       Date:  1997-08

Review 2.  Drug dosage in patients during continuous renal replacement therapy. Pharmacokinetic and therapeutic considerations.

Authors:  P Reetze-Bonorden; J Böhler; E Keller
Journal:  Clin Pharmacokinet       Date:  1993-05       Impact factor: 6.447

3.  Comparison of the effects of three haemodialysis membranes on vancomycin disposition.

Authors:  J Alwakeel; T A Najjar; M J al-Yamani; S Huraib; A al-Haider; H Abu-aisha
Journal:  Int Urol Nephrol       Date:  1994       Impact factor: 2.370

Review 4.  Pharmacokinetic optimisation of vancomycin therapy.

Authors:  W G Leader; M H Chandler; M Castiglia
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

5.  Molecular Adsorbent Recirculating System Therapy with Continuous Renal Replacement Therapy Enhanced Clearance of Piperacillin in a Pediatric Patient and Led to Failure to Attain Pharmacodynamic Targets.

Authors:  Sonya Tang Girdwood; Trent Arbough; Min Dong; Tomoyuki Mizuno; Peter Tang; Alexander A Vinks; Jennifer Kaplan
Journal:  Pharmacotherapy       Date:  2020-10-08       Impact factor: 4.705

6.  Construction of a prediction model for drug removal rate in hemodialysis based on chemical structures.

Authors:  Kousuke Nishikiori; Kentaro Tanaka; Yoshihiro Uesawa
Journal:  Mol Divers       Date:  2022-01-01       Impact factor: 3.364

7.  In vivo evaluation of drug dialyzability in a rat model of hemodialysis.

Authors:  Masaki Fukunaga; Daisuke Kadowaki; Mika Mori; Satomi Hagiwara; Yuki Narita; Junji Saruwatari; Ryota Tanaka; Hiroshi Watanabe; Keishi Yamasaki; Kazuaki Taguchi; Hiroki Ito; Toru Maruyama; Masaki Otagiri; Sumio Hirata
Journal:  PLoS One       Date:  2020-06-12       Impact factor: 3.240

8.  Evaluation of Factors which Influence Mortality in Gram-positive Bacteremia in Hemodialysis Patients.

Authors:  Kerry Anne Rambaran; Saeed K Alzghari; Charles F Seifert
Journal:  Cureus       Date:  2018-07-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.